KOSDAQBiotech & Pharma334970

Prestige Biologics

₩1,065▼ 2.38%2026-11-18 close
Market Cap
₩82.8B
Turnover
₩200M
Volume
230K
Shares out.
77.8M
PER
—
PBR
1.1×
EPS
-₩567
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue up sharply, but losses persist at this CDMO

Revenue reached KRW 26.7 billion in the fiscal year ended June 2026 and has risen for three straight fiscal years, but the operating loss widened to KRW 49.3 billion, so a return to profit is not yet visible.

  1. 1

    Revenue growth: KRW 26.7 billion in the fiscal year ended June 2026, up 112.8% year on year, with increases in each of the last three fiscal years.

  2. 2

    Losses continue: the fiscal year ended June 2026 posted an operating loss of KRW 49.3 billion and a net loss attributable to controlling shareholders of KRW 51.2 billion. The operating margin narrowed to -184.9% from -1,277.6% in the fiscal year ended June 2023.

  3. 3

    Quarterly trend: the operating loss in the third quarter of 2026 was KRW 4.39 billion, narrower than KRW 13.6 billion a year earlier. The net loss attributable to controlling shareholders over the last four quarters totals KRW 44.1 billion.

  4. 4

    Order base: cumulative orders reached KRW 65 billion as of the end of March 2026, and a KRW 15.5 billion commercial API manufacturing contract was disclosed in November 2026.

  5. 5

    Balance sheet: total liabilities were KRW 176.1 billion at the end of June 2026, and the debt ratio rose to 194.7% from 99.9% in the fiscal year ended June 2025. Operating cash flow turned to an inflow of KRW 3.2 billion.

02

Business structure

Prestige Biologics is a CDMO that manufactures antibody drugs on contract. Its production base consists of four plants with a total capacity of 154,000 liters, and the first plant is a campus with EU GMP certification.

An external corporate data aggregator shows antibody drugs at 52% of sales and service and other revenue at 48% as of March 2026, but this is a third-party classification and is treated here as reference only.

On regulation, the company has secured GMP approval from Korea's MFDS and Europe, followed by approval from Brazil's ANVISA. Its customers range from domestic drugmakers such as Alteogen and Celltrion to new-technology biotech firms, as the company stated in April 2024.

Besides contract manufacturing, the company runs contract testing and contract packaging (CPO) services, and reported more than four CPO orders. A contract disclosed on November 12, 2026 covers a commercial API manufacturing deal worth about KRW 15.5 billion, with a contract period running through December 31, 2027.

Half of the contract value is to be received as an advance payment. The company says its single-use culture method, which uses disposable culture bags, reduces cross-contamination risk and supports cost competitiveness.

In competition, plant scale and commercial production track record determine order competitiveness, and the gap is most visible against large CDMO peers such as Samsung Biologics and Celltrion. The company is strengthening a scale-bridge strategy that links clinical development to commercial production.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.2B-₩13.6B−1163.4%
2025Q4₩8.9B-₩9.7B−109.5%
2026Q1₩2.3B-₩16.3B−719.4%
2026Q2₩14.3B-₩9.6B−67.3%
2026Q3₩4B-₩4.4B−109.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2023.06₩1.7B-₩22.1B-₩18B−1277.6%−18.0%206.4%
2024.06₩2.2B-₩33.4B-₩29.4B−1541.2%−41.0%303.7%
2025.06₩12.5B-₩33.7B-₩27.5B−268.7%−20.3%99.9%
2026.06₩26.7B-₩49.3B-₩51.2B−184.9%−56.6%194.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual revenue rose from KRW 1.73 billion in the fiscal year ended June 2023 to KRW 26.7 billion in the fiscal year ended June 2026.

Revenue was KRW 2.17 billion in the fiscal year ended June 2024 (up 25.4%), KRW 12.5 billion in the fiscal year ended June 2025 (up 477.8%), and KRW 26.7 billion in the fiscal year ended June 2026 (up 112.8%), so it has grown for three straight fiscal years since June 2024.

Over the same period the operating loss was KRW 22.1 billion, KRW 33.4 billion, KRW 33.7 billion and KRW 49.3 billion, so losses have continued each year. The operating margin improved from -1,277.6% to -184.9%, but that reflects the larger revenue base, while the absolute loss widened.

The net loss attributable to controlling shareholders grew from KRW 18 billion in the fiscal year ended June 2023 to KRW 51.2 billion in the fiscal year ended June 2026, after narrowing to KRW 27.5 billion in the fiscal year ended June 2025.

The company attributes the increase in losses mainly to impairment charges on inventory, convertible bonds and some production facilities. The company argues that these accounting impairments have a limited effect on actual cash flow.

Operating cash flow moved from outflows of KRW 4.45 billion in the fiscal year ended June 2023 and KRW 18.3 billion in the fiscal year ended June 2025 to an inflow of KRW 3.2 billion in the fiscal year ended June 2026.

Quarterly revenue was KRW 1.17 billion in the third quarter of 2025, KRW 8.9 billion in the fourth quarter of 2025, KRW 2.27 billion in the first quarter of 2026, KRW 14.3 billion in the second quarter of 2026 and KRW 4.03 billion in the third quarter of 2026.

The company said revenue exceeded KRW 10 billion for the first time in the April to June 2026 quarter. The swings appear to reflect timing, since new contract volumes convert into production and revenue in sequence.

The operating loss was KRW 4.39 billion in the third quarter of 2026, down from KRW 13.6 billion a year earlier, but the net loss attributable to controlling shareholders over the last four quarters totals KRW 44.1 billion.

05

Industry analysis

Demand for CDMO services is expanding alongside biosimilar production. The company is described as growing its biosimilar CDMO orders, including contracts from overseas firms.

Contract testing is described as a market that emerged as demand grew for early-stage work in GMP facilities that meet international standards from the outset.

The company's statement that it is moving from securing orders to converting them into production and revenue suggests the industry is in a middle phase, shifting from order expansion to utilization management.

Large CDMO companies focus on large long-term contracts, while this company targets clinical supply and scale-up volumes with mid-sized capacity. Celltrion both produces its own drugs and is a customer of this company, which shows how orders and production are intertwined in the sector.

GMP inspection readiness is a precondition for orders, and in 2025 reporting the company said it was preparing for a US FDA cGMP certification at its fourth plant.

Utilization management and cost pressure from the shift to commercial production are common industry challenges, and the company's impairment cases can be read in that context. Whether order growth translates into earnings should be judged together with utilization and cost trends.

06

Outlook

The company said cumulative orders stood at KRW 65 billion as of the end of March 2026. During the fiscal year ended June 2026 it signed a total of six new CDMO contracts with domestic and overseas customers, worth about KRW 41.2 billion.

The KRW 15.5 billion contract disclosed in November 2026 runs through December 31, 2027, so production and revenue recognition are likely to extend through 2027. The follow-on clinical supply contract runs through the end of March 2027.

The company expects an operating margin improvement from restructuring its cost recognition, in which raw material costs had been booked ahead of revenue. Reporting in 2025 said the first plant exceeded 70% utilization at peak batch capacity, and that the second and fourth plants were producing contracted volumes.

Because that figure dates from 2025, it should not be read as current utilization. Three points remain to be checked. First, how quickly the order backlog converts into quarterly revenue. Second, whether inventory and facility impairments recur. Third, how much higher utilization lowers the operating margin loss. All three can be checked in the next periodic reports.

07

Valuation

PER
—
PBR
1.1×
ROE
-42.6%
EPS
-₩567
BPS
₩1,090
Dividend per share
₩0

The price-to-book ratio sits in a range where the premium over net assets is not large.

Total equity is KRW 90.5 billion, and the portion attributable to controlling shareholders is the same, but total liabilities of KRW 176.1 billion are close to twice equity, so the debt structure must be considered alongside asset value.

Because net losses attributable to controlling shareholders have continued over the last four quarters, a price-to-earnings ratio cannot be calculated. Comparison therefore centers on net asset value rather than earnings-based multiples.

The company pays no dividend, so its dividend yield sits below the industry average. Convertible bonds are outstanding, so potential changes in share count are part of any value comparison. Comparing against a historical valuation band has limited meaning because the company has had few profitable periods.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Top-line growth and order accumulation

Revenue in the fiscal year ended June 2026 reached KRW 26.7 billion, up 112.8% year on year, with growth in each of the last three fiscal years. Cumulative orders stood at KRW 65 billion as of the end of March 2026.

The KRW 15.5 billion contract disclosed in November 2026 includes an advance payment of half its value, which secures both production volume and funding.

Improving operating margin trend

The operating margin improved from -1,277.6% in the fiscal year ended June 2023 to -184.9% in the fiscal year ended June 2026. The operating loss in the third quarter of 2026 was KRW 4.39 billion, down from KRW 13.6 billion in the third quarter of 2025. The company said it raised cost-control efficiency by changing how raw material costs were booked.

Cash flow turn and utilization headroom

Operating cash flow turned to an inflow of KRW 3.2 billion in the fiscal year ended June 2026. Reporting in 2025 said the first plant exceeded 70% utilization at peak batch capacity. Higher utilization could ease fixed-cost pressure, which is the core of the bullish case.

09

Bear factors

Losses continue and widened

The fiscal year ended June 2026 posted an operating loss of KRW 49.3 billion and a net loss attributable to controlling shareholders of KRW 51.2 billion, with losses continuing on both measures. The net loss attributable to controlling shareholders widened from KRW 27.5 billion in the fiscal year ended June 2025.

Debt burden and convertible bonds

Total liabilities were KRW 176.1 billion at the end of June 2026, and the debt ratio rose to 194.7% from 99.9% in the fiscal year ended June 2025. Convertible bonds are outstanding, so interest costs and potential dilution must be considered together. If impairments on inventory and facilities recur, the capital base could weaken further.

Large swings in quarterly revenue

Quarterly revenue swung from KRW 2.27 billion in the first quarter of 2026 to KRW 14.3 billion in the second quarter and KRW 4.03 billion in the third quarter. Earnings depend on when new contract volumes move into production and revenue. If production schedules slip, quarterly revenue could fall again, which limits the predictability of results.

10

Risk factors

Financial and liquidity

The debt ratio is 194.7%, with total liabilities close to twice total equity. The company says the cash impact of impairments is limited, but the repayment schedule and refinancing options will determine the funding burden. Conversion or redemption terms of the convertible bonds also affect the capital structure.

Contract execution and production

The company must deliver on the KRW 15.5 billion contract disclosed in November 2026 and on about KRW 41.2 billion of contracts signed during the fiscal year ended June 2026. Customers and products are largely undisclosed under confidentiality terms, which makes order quality hard to verify from outside. Production delays could affect revenue recognition and the settlement of advance payments.

Regulatory and quality

A CDMO business depends on passing GMP inspections and meeting quality standards. Reporting in 2025 said preparations for US FDA cGMP certification were underway, but the timing and outcome of that certification have not been confirmed. Inspection findings or quality problems could affect both new orders and existing contracts.

11

What to watch next

  1. Mid-February 2027

    The semiannual report covering October to December 2026 is due. The key checks are whether the operating margin improves, whether inventory and facility impairments recur, and whether revenue rises alongside production under the KRW 15.5 billion contract.

  2. End of March 2027

    The clinical supply contract period ends. The checkpoints are whether it converts into commercial production contracts and whether cumulative orders are updated.

  3. End of September 2027

    This is the deadline for the annual business report for the fiscal year ending June 2027. The checkpoints are whether annual revenue keeps rising year on year and whether the operating loss narrows from the KRW 49.3 billion posted in the fiscal year ended June 2026.

  4. December 31, 2027

    The contract period for the KRW 15.5 billion commercial API manufacturing contract ends. The checkpoints are whether the contract is fully executed and how much revenue is recognized.

12

Overall view

Prestige Biologics recorded revenue of KRW 26.7 billion in the fiscal year ended June 2026, up 112.8% year on year, so its top-line expansion is now showing up in reported results.

The same year brought an operating loss of KRW 49.3 billion and a net loss attributable to controlling shareholders of KRW 51.2 billion, and the loss amount grew alongside revenue. The operating margin's improvement to -184.9% reflects the larger revenue base.

The narrower operating loss in the third quarter of 2026 and the turn to positive operating cash flow are read as bullish signals. Meanwhile, the 194.7% debt ratio, the convertible bonds and the quarterly revenue swings remain items to verify for financial stability and earnings predictability.

The company says impairments have a limited cash effect, but that explanation should be tested against the size and recurrence of impairments in the next periodic reports.

Cumulative orders of KRW 65 billion and the KRW 15.5 billion contract show the order base, but the speed at which they convert into revenue is the key to earnings improvement.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. getnews.co.kr
  2. m.thinkpool.com
  3. newspim.com
  4. view.asiae.co.kr
  5. newspim.com
  6. jobkorea.co.kr
  7. judal.co.kr
  8. judal.co.kr
  9. press9.kr
  10. edaily.co.kr
  11. hankyung.com
  12. edaily.co.kr
  13. press9.kr
  14. medicopharma.co.kr
  15. edaily.co.kr
  16. news.nate.com
  17. edaily.co.kr
  18. thebionews.net

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis